Search Results

Canakinumab Case Study | Philip Conaghan

Canakinumab Case Study | Philip Conaghan

The Canakinumab Anti-Inflammatory Thrombosis Outcomes Study at ESC 2017.

The Canakinumab Anti-Inflammatory Thrombosis Outcomes Study at ESC 2017.

"Structure" and Disease Modifying Osteoarthritis Drugs | Sharmila Majumdar and Philip Conaghan

"Structure" and Disease Modifying Osteoarthritis Drugs | Sharmila Majumdar and Philip Conaghan

Professor Phillip Conaghan talks AposTherapy knee pain treatment

Professor Phillip Conaghan talks AposTherapy knee pain treatment

RheumNow Live Preview with Dr. Philip Conaghan (Distinguishing PsA from OA)

RheumNow Live Preview with Dr. Philip Conaghan (Distinguishing PsA from OA)

NIHR Leeds Biomedical Research Centre Past and Future - Prof Paul Emery OBE and Prof Philip Conaghan

NIHR Leeds Biomedical Research Centre Past and Future - Prof Paul Emery OBE and Prof Philip Conaghan

CANOPY-A: canakinumab for early stage NSCLC

CANOPY-A: canakinumab for early stage NSCLC

Future Imaging in PsA with Dr. Phillip Conaghan

Future Imaging in PsA with Dr. Phillip Conaghan

Experts Discuss TJR, Endpoints, and Pain in Clinical Trials for Osteoarthritis Drug Development

Experts Discuss TJR, Endpoints, and Pain in Clinical Trials for Osteoarthritis Drug Development

[OACS Clip] Hope for New Therapies in OA?

[OACS Clip] Hope for New Therapies in OA?

[OACS Clip] STRONG QUADS ARE GOLD (FOR KNEE OA)

[OACS Clip] STRONG QUADS ARE GOLD (FOR KNEE OA)

Ilaris

Ilaris